USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
USA Neurvati Neurosciences is carving a distinctive path in one of medicine’s most high-risk arenas: neuroscience. In this interview, President and CEO Dr Bruce Leuchter explains how a private equity-inspired model, backed by Blackstone Life Sciences, is enabling the company to advance late-stage assets, forge global partnerships, and build a values-driven…
See our Cookie Privacy Policy Here
